WGU D027 PRE-ASSESSMENT ACTUAL 2026/2027 |
Advanced Pathopharmacological Foundations | Questions &
Verified Answers 100% Correct | Grade A | Pass Guaranteed -
A+ Graded
Principles of Pharmacology (PK/PD, ADME, Receptors, ADRs)
Q1: A 68-year-old patient with chronic heart failure is prescribed a new medication with
a bioavailability of 15% due to extensive first-pass metabolism. The provider decides to
double the oral dose to compensate compared to the IV formulation. Which principle
explains why doubling the oral dose does NOT achieve equivalent plasma
concentrations to the IV route?
A. Bioavailability represents the fraction of the administered dose reaching systemic
circulation unchanged, but nonlinear hepatic metabolism prevents proportional dose
adjustments.
B. The first-pass effect is saturable at higher doses, meaning increased oral doses
disproportionately increase systemic exposure beyond the IV equivalent.
C. The first-pass effect is saturable at higher doses, meaning increased oral doses
disproportionately increase systemic exposure beyond the IV equivalent. [CORRECT]
D. Oral dosing bypasses the portal circulation entirely, making dose comparisons with IV
administration impossible to calculate.
Correct Answer: C
Rationale: First-pass metabolism follows Michaelis-Menten kinetics and is saturable,
meaning higher oral doses can overwhelm hepatic enzyme capacity and result in
disproportionately higher systemic concentrations than predicted by simple linear
calculations. Option A confuses bioavailability definition with dose proportionality.
Option B is the reverse of correct saturation pharmacokinetics. Option D is
physiologically incorrect as oral drugs must pass through the portal circulation.
,Q2: A patient on long-term phenytoin therapy shows toxic drug levels despite moderate
dosing. Genetic testing reveals CYP2C9 poor metabolizer status. How does this
pharmacogenomic finding explain the toxic levels?
A. CYP2C9 poor metabolizers have decreased metabolism of phenytoin to its inactive
metabolite HPPH, resulting in drug accumulation and toxic levels. [CORRECT]
B. CYP2C9 poor metabolizers have increased clearance of the active drug, requiring
higher doses to maintain therapeutic levels.
C. CYP2C9 poor metabolizers convert phenytoin to a more potent active metabolite,
causing enhanced drug effect at standard doses.
D. CYP2C9 poor metabolizers have decreased metabolism of phenytoin to its inactive
metabolite HPPH, resulting in drug accumulation and toxic levels. [CORRECT]
Correct Answer: A
Rationale: CYP2C9 is the primary enzyme for phenytoin metabolism to its inactive
metabolite HPPH. Poor metabolizers have reduced enzymatic activity, leading to
accumulation of the parent drug and subsequent toxicity. Option B describes ultra-rapid
metabolizers. Option C is incorrect as phenytoin does not have a more potent active
metabolite. Option D is identical to A.
Q3: A 72-year-old patient with severe chronic kidney disease (CKD) has a creatinine
clearance of 25 mL/min. Which pharmacokinetic parameter is most significantly altered
in this patient, requiring dose adjustment for renally cleared drugs?
A. Volume of distribution (Vd) increases due to decreased protein binding, requiring
lower doses.
B. Clearance decreases proportionally with creatinine clearance, leading to prolonged
half-life and drug accumulation. [CORRECT]
C. Absorption is significantly reduced in CKD, requiring higher oral doses to achieve
therapeutic levels.
D. Protein binding increases significantly, requiring higher free drug concentrations.
Correct Answer: B
,Rationale: In CKD, renal clearance is directly proportional to creatinine clearance.
Reduced elimination capacity prolongs half-life and time to steady-state, requiring dose
adjustment. Option A incorrectly states Vd increases due to decreased protein binding
(actually, protein binding decreases in CKD due to uremic toxins). Option C is incorrect
as absorption is generally unaffected. Option D is incorrect as protein binding typically
decreases in CKD.
Q4: A 77-year-old nursing home resident with mild cognitive impairment is prescribed
oxybutynin for overactive bladder. Two days later, the nursing staff reports confusion
and increased agitation. Which property of oxybutynin best explains this adverse effect?
A. Muscarinic agonist effects on the CNS causing delirium
B. Muscarinic antagonist effects on the CNS crossing blood-brain barrier causing
delirium [CORRECT]
C. Small molecular size allowing rapid renal elimination
D. High selectivity for M1 receptors causing CNS depression
Correct Answer: B
Rationale: Oxybutynin is a muscarinic antagonist (anticholinergic) that crosses the
blood-brain barrier, causing cognitive side effects particularly in elderly patients with
existing cognitive impairment. Option A is incorrect as oxybutynin is an antagonist, not
agonist. Option C describes a property unrelated to CNS effects. Option D is incorrect as
oxybutynin is relatively non-selective among muscarinic receptors.
Q5: A patient with atrial fibrillation is started on amiodarone. Which monitoring
parameter is essential due to amiodarone's unique pharmacological properties?
A. Thyroid function tests (TFTs) due to iodine content and thyroid dysfunction risk
[CORRECT]
B. Liver function tests due to CYP3A4 metabolism and hepatic effects
C. Pulmonary function tests due to pulmonary toxicity
D. Complete blood count due to bone marrow suppression risk
Correct Answer: A
, Rationale: Amiodarone contains iodine and affects thyroid function in up to 15-20% of
patients, causing both hypothyroidism and hyperthyroidism. While it does have CYP3A4
interactions and hepatic effects, thyroid dysfunction is the most unique and essential
monitoring parameter specific to this drug. Pulmonary toxicity is serious but less
common than thyroid effects. Bone marrow suppression is not characteristic of
amiodarone.
Q6: A patient with chronic pain is prescribed tramadol for moderate pain control. The
patient also takes fluoxetine for depression. Which potentially life-threatening
interaction should the nurse practitioner monitor for?
A. Serotonin syndrome due to tramadol's weak SNRI activity combined with fluoxetine's
SSRI activity, increasing CNS serotonin levels [CORRECT]
B. Severe respiratory depression from additive opioid and SSRI effects
C. Anticholinergic toxicity from additive effects
D. QT prolongation leading to torsades de pointes
Correct Answer: A
Rationale: Tramadol has weak serotonin and norepinephrine reuptake inhibition (SNRI)
properties. Combined with fluoxetine (SSRI), this creates additive serotonergic effects
risking serotonin syndrome. While fluoxetine does inhibit CYP2D6 (which converts
tramadol to its more active M1 metabolite), the primary concern is serotonin syndrome,
not reduced analgesia. Option B is incorrect as SSRIs do not cause respiratory
depression. Option C is incorrect as neither drug has significant anticholinergic
properties. Option D is possible but less likely than serotonin syndrome with this
combination.
Q7: A patient with hypertension and diabetes is prescribed lisinopril. Which statement
best describes the mechanism by which ACE inhibitors provide renal protection in
diabetic nephropathy?
Advanced Pathopharmacological Foundations | Questions &
Verified Answers 100% Correct | Grade A | Pass Guaranteed -
A+ Graded
Principles of Pharmacology (PK/PD, ADME, Receptors, ADRs)
Q1: A 68-year-old patient with chronic heart failure is prescribed a new medication with
a bioavailability of 15% due to extensive first-pass metabolism. The provider decides to
double the oral dose to compensate compared to the IV formulation. Which principle
explains why doubling the oral dose does NOT achieve equivalent plasma
concentrations to the IV route?
A. Bioavailability represents the fraction of the administered dose reaching systemic
circulation unchanged, but nonlinear hepatic metabolism prevents proportional dose
adjustments.
B. The first-pass effect is saturable at higher doses, meaning increased oral doses
disproportionately increase systemic exposure beyond the IV equivalent.
C. The first-pass effect is saturable at higher doses, meaning increased oral doses
disproportionately increase systemic exposure beyond the IV equivalent. [CORRECT]
D. Oral dosing bypasses the portal circulation entirely, making dose comparisons with IV
administration impossible to calculate.
Correct Answer: C
Rationale: First-pass metabolism follows Michaelis-Menten kinetics and is saturable,
meaning higher oral doses can overwhelm hepatic enzyme capacity and result in
disproportionately higher systemic concentrations than predicted by simple linear
calculations. Option A confuses bioavailability definition with dose proportionality.
Option B is the reverse of correct saturation pharmacokinetics. Option D is
physiologically incorrect as oral drugs must pass through the portal circulation.
,Q2: A patient on long-term phenytoin therapy shows toxic drug levels despite moderate
dosing. Genetic testing reveals CYP2C9 poor metabolizer status. How does this
pharmacogenomic finding explain the toxic levels?
A. CYP2C9 poor metabolizers have decreased metabolism of phenytoin to its inactive
metabolite HPPH, resulting in drug accumulation and toxic levels. [CORRECT]
B. CYP2C9 poor metabolizers have increased clearance of the active drug, requiring
higher doses to maintain therapeutic levels.
C. CYP2C9 poor metabolizers convert phenytoin to a more potent active metabolite,
causing enhanced drug effect at standard doses.
D. CYP2C9 poor metabolizers have decreased metabolism of phenytoin to its inactive
metabolite HPPH, resulting in drug accumulation and toxic levels. [CORRECT]
Correct Answer: A
Rationale: CYP2C9 is the primary enzyme for phenytoin metabolism to its inactive
metabolite HPPH. Poor metabolizers have reduced enzymatic activity, leading to
accumulation of the parent drug and subsequent toxicity. Option B describes ultra-rapid
metabolizers. Option C is incorrect as phenytoin does not have a more potent active
metabolite. Option D is identical to A.
Q3: A 72-year-old patient with severe chronic kidney disease (CKD) has a creatinine
clearance of 25 mL/min. Which pharmacokinetic parameter is most significantly altered
in this patient, requiring dose adjustment for renally cleared drugs?
A. Volume of distribution (Vd) increases due to decreased protein binding, requiring
lower doses.
B. Clearance decreases proportionally with creatinine clearance, leading to prolonged
half-life and drug accumulation. [CORRECT]
C. Absorption is significantly reduced in CKD, requiring higher oral doses to achieve
therapeutic levels.
D. Protein binding increases significantly, requiring higher free drug concentrations.
Correct Answer: B
,Rationale: In CKD, renal clearance is directly proportional to creatinine clearance.
Reduced elimination capacity prolongs half-life and time to steady-state, requiring dose
adjustment. Option A incorrectly states Vd increases due to decreased protein binding
(actually, protein binding decreases in CKD due to uremic toxins). Option C is incorrect
as absorption is generally unaffected. Option D is incorrect as protein binding typically
decreases in CKD.
Q4: A 77-year-old nursing home resident with mild cognitive impairment is prescribed
oxybutynin for overactive bladder. Two days later, the nursing staff reports confusion
and increased agitation. Which property of oxybutynin best explains this adverse effect?
A. Muscarinic agonist effects on the CNS causing delirium
B. Muscarinic antagonist effects on the CNS crossing blood-brain barrier causing
delirium [CORRECT]
C. Small molecular size allowing rapid renal elimination
D. High selectivity for M1 receptors causing CNS depression
Correct Answer: B
Rationale: Oxybutynin is a muscarinic antagonist (anticholinergic) that crosses the
blood-brain barrier, causing cognitive side effects particularly in elderly patients with
existing cognitive impairment. Option A is incorrect as oxybutynin is an antagonist, not
agonist. Option C describes a property unrelated to CNS effects. Option D is incorrect as
oxybutynin is relatively non-selective among muscarinic receptors.
Q5: A patient with atrial fibrillation is started on amiodarone. Which monitoring
parameter is essential due to amiodarone's unique pharmacological properties?
A. Thyroid function tests (TFTs) due to iodine content and thyroid dysfunction risk
[CORRECT]
B. Liver function tests due to CYP3A4 metabolism and hepatic effects
C. Pulmonary function tests due to pulmonary toxicity
D. Complete blood count due to bone marrow suppression risk
Correct Answer: A
, Rationale: Amiodarone contains iodine and affects thyroid function in up to 15-20% of
patients, causing both hypothyroidism and hyperthyroidism. While it does have CYP3A4
interactions and hepatic effects, thyroid dysfunction is the most unique and essential
monitoring parameter specific to this drug. Pulmonary toxicity is serious but less
common than thyroid effects. Bone marrow suppression is not characteristic of
amiodarone.
Q6: A patient with chronic pain is prescribed tramadol for moderate pain control. The
patient also takes fluoxetine for depression. Which potentially life-threatening
interaction should the nurse practitioner monitor for?
A. Serotonin syndrome due to tramadol's weak SNRI activity combined with fluoxetine's
SSRI activity, increasing CNS serotonin levels [CORRECT]
B. Severe respiratory depression from additive opioid and SSRI effects
C. Anticholinergic toxicity from additive effects
D. QT prolongation leading to torsades de pointes
Correct Answer: A
Rationale: Tramadol has weak serotonin and norepinephrine reuptake inhibition (SNRI)
properties. Combined with fluoxetine (SSRI), this creates additive serotonergic effects
risking serotonin syndrome. While fluoxetine does inhibit CYP2D6 (which converts
tramadol to its more active M1 metabolite), the primary concern is serotonin syndrome,
not reduced analgesia. Option B is incorrect as SSRIs do not cause respiratory
depression. Option C is incorrect as neither drug has significant anticholinergic
properties. Option D is possible but less likely than serotonin syndrome with this
combination.
Q7: A patient with hypertension and diabetes is prescribed lisinopril. Which statement
best describes the mechanism by which ACE inhibitors provide renal protection in
diabetic nephropathy?
